HCAT PE Ratio & Valuation, Is HCAT Overvalued

Historical Valuation

Health Catalyst Inc (HCAT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.54 is considered Fairly compared with the five-year average of -23.68. The fair price of Health Catalyst Inc (HCAT) is between 1.06 to 17.39 according to relative valuation method.

Relative Value

Fair Zone

1.06-17.39

Current Price：1.82

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Health Catalyst Inc (HCAT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Health Catalyst Inc (HCAT) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 1.15, the current P/B ratio is approximately -57.94% higher. Relative to its 5-year average P/B ratio of 2.39, the current P/B ratio is about -79.70% higher. Health Catalyst Inc (HCAT) has a Forward Free Cash Flow (FCF) yield of approximately -8.57%. Compared to its 3-year average FCF yield of -3.75%, the current FCF yield is approximately 128.61% lower. Relative to its 5-year average FCF yield of -3.39%, the current FCF yield is about 152.78% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for HCAT competitors is 0.87, providing a benchmark for relative valuation. Health Catalyst Inc Corp (HCAT.O) exhibits a P/S ratio of 0.54, which is -38.5% above the industry average. Given its robust revenue growth of -0.04%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of HCAT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HCAT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HCAT currently overvalued or undervalued?

What is Health Catalyst Inc (HCAT) fair value?

HCAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Health Catalyst Inc (HCAT) is between 1.06 to 17.39 according to relative valuation method.

How does HCAT's valuation metrics compare to the industry average?

The average P/S ratio for HCAT's competitors is 0.87, providing a benchmark for relative valuation. Health Catalyst Inc Corp (HCAT) exhibits a P/S ratio of 0.54, which is -38.50% above the industry average. Given its robust revenue growth of -0.04%, this premium appears unsustainable.

What is the current P/B ratio for Health Catalyst Inc (HCAT) as of Mar 10 2026?

As of Mar 10 2026, Health Catalyst Inc (HCAT) has a P/B ratio of 0.49. This indicates that the market values HCAT at 0.49 times its book value.

What is the current FCF Yield for Health Catalyst Inc (HCAT) as of Mar 10 2026?

As of Mar 10 2026, Health Catalyst Inc (HCAT) has a FCF Yield of -8.57%. This means that for every dollar of Health Catalyst Inc's market capitalization, the company generates -8.57 cents in free cash flow.

What is the current Forward P/E ratio for Health Catalyst Inc (HCAT) as of Mar 10 2026?

As of Mar 10 2026, Health Catalyst Inc (HCAT) has a Forward P/E ratio of 6.35. This means the market is willing to pay $6.35 for every dollar of Health Catalyst Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Health Catalyst Inc (HCAT) as of Mar 10 2026?

As of Mar 10 2026, Health Catalyst Inc (HCAT) has a Forward P/S ratio of 0.54. This means the market is valuing HCAT at $0.54 for every dollar of expected revenue over the next 12 months.

HCAT Valuation